Pulmonary Vasculature

Latest News

Longitudinal Value of Questionnaires for Health-Related QoL in PAH

Health-related quality of life questionnaires created for pulmonary hypertension may be useful for clinicians in daily practice.

Inhaled Imatinib Designated an Orphan Drug for PAH

AER-901 is an investigational drug-device combination therapy that consists of a nebulized formulation of imatinib and the Fox device, a breath-actuated smart nebulizer.

Heparin to Dabigatran Switch Safe, Effective in Patients With Intermediate-Risk Pulmonary Embolism

Researchers assessed whether treatment of acute intermediate-risk pulmonary embolism with parenteral anticoagulation followed by a switch to a direct oral anticoagulant was effective and safe.

Preop Isolation May Up Risk for Postop Pulmonary Complications

Pandemic-related preoperative isolation linked to higher rates of postoperative pulmonary complications following elective surgery.

FDA Approves IV Formulation of Uptravi for Pulmonary Arterial Hypertension

The approval was based on data from a single sequence cross-over phase 3 study that evaluated the safety, tolerability and pharmacokinetics of temporarily switching between the tablet and IV formulation.

CFTR Expression in the Pathogenesis of Pulmonary Arterial Hypertension

Researchers sought to delineate the role of cystic fibrosis transmembrane conductance regulator (CFTR) in pulmonary arterial hypertension pathogenesis through observational and interventional experiments in human tissues and animal models.

Cardiac Axis Deviation in Systemic Sclerosis-Related Pulmonary Hypertension

Study investigators assessed whether cardiac axis deviation may indicate cardiac function abnormalities, allowing for predictions of disease severity and mortality.

FDA to Review Dry Powder Inhalation Formulation of Treprostinil

Tyvaso DPI is an investigational drug-device combination therapy consisting of a dry powder formulation of treprostinil.

Safety and Feasibility of Treprostinil Pump Implantation in PAH

Avoiding intubation and mechanical ventilation during subcutaneous pump implantation under local anesthesia and conscious analgosedation was feasible in patients with pulmonary arterial hypertension.

Sotatercept Leads to PVR Reductions in Pulmonary Arterial Hypertension

In patients with pulmonary arterial hypertension (PAH) receiving background therapy, treatment with sotatercept led to significant reductions in pulmonary vascular resistance.